for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

MEDINET CO., LTD.

2370.T

Latest Trade

77.00JPY

Change

--(--)

Today's Range

--

 - 

--

52 Week Range

51.00

 - 

127.00

As of on the Tokyo Stock Exchange ∙ Minimum 15 minute delay

Pricing

Previous Close
77.00
Open
--
Volume
--
3M AVG Volume
299.88
Today's High
--
Today's Low
--
52 Week High
127.00
52 Week Low
51.00
Shares Out (MIL)
177.73
Market Cap (MIL)
13,685.24
Forward P/E
--
Dividend (Yield %)
--

Next Event

Q3 2021 Medinet Co Ltd Earnings Release

Latest Developments

More

Medinet to merge with units

Medinet announces result of early-retirement program

Histogenics And Medinet Enter Licensing Agreement For Commercialization Of NeoCart In Japan

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About MEDINET CO., LTD.

MEDINET Co., Ltd. is a Japan-based company mainly engaged in cell processing industry and cellular medical products business. It operates through two business segments. The Cell Processing Industry segment mainly engages in comprehensive support services for immune cell therapy, related services including clinical use from companies, universities, research institutes, outsourcing of cell processing for clinical trials and operation of cell culture processing facilities. The Cellular Medical Products segment is mainly engaged in research and development for obtaining approval for manufacture and marketing of cellular medical products. It also provides comprehensive support services for immune cell therapy.

Industry

Biotechnology & Drugs

Contact Info

9F, TRC Center Bldg., 6-1-1, Heiwajima

OTA-KU, TKY

143-0006

Japan

+81.3.66311201

https://www.medinet-inc.co.jp/

Executive Leadership

Yoshiji Kimura

Chairman of the Board, President, Chief Director of Business, Representative Director

Kunihiko Suzuki

Vice Chairman of the Board

Daisuke Hara

Executive Officer, Chief Director of Administration, Director

Yoshiaki Haruyama

Executive Officer, Director of TR Promotion

Hiromu Miyamoto

Chief Director of Administration, Director

Key Stats

Price To Earnings (TTM)
--
Price To Sales (TTM)
24.81
Price To Book (MRQ)
2.55
Price To Cash Flow (TTM)
--
Total Debt To Equity (MRQ)
0.00
LT Debt To Equity (MRQ)
0.00
Return on Investment (TTM)
-22.93
Return on Equity (TTM)
-21.56

Latest News

Latest News

BRIEF-Medinet Sees About An 10% To 15% Increase In Its Consolidated Net Loss For Year

* SEES ABOUT AN 10% TO 15% INCREASE IN ITS CONSOLIDATED NET LOSS FOR YEAR

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up